ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

160 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Phase 2Pediatric Epileptic SyndromePartial-onset Seizures

Perampanel Oral SuspensionPerampanel Tablet

Eisai Inc.100 participants49 sites · United States, Belgium, CzechiaCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Phase 1Phase 2Chronic Inflammatory Demyelinating PolyradiculoneuropathyNMO Spectrum DisorderMyasthenia Gravis

BAFF-R CART

Tianjin Medical University General Hospital27 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Phase 2Early Alzheimer's Disease

MK-2214Placebo

Merck Sharp & Dohme LLC340 participants78 sites · United States, Argentina, AustraliaCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants2 sites · United StatesCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Phase 3Alzheimers Disease

TrontinemabPlacebo

Hoffmann-La Roche800 participants143 sites · United States, Argentina, BrazilCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3Dravet Syndrome

zorevunersenSham Comparator

Stoke Therapeutics, Inc170 participants61 sites · United States, France, GermanyCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Phase 1Phase 2Amyotrophic Lateral Sclerosis (ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene

ALN-SODDiluentPlacebo (PB)

Regeneron Pharmaceuticals42 participants16 sites · Australia, Belgium, CanadaCompletes Jun 2031

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Phase 3Alzheimer's Disease

KarXTKarX-ECPlacebo

Bristol-Myers Squibb586 participants124 sites · United States, Argentina, AustraliaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3Dravet Syndrome

Clemizole HClPlacebo

Epygenix150 participants58 sites · United States, Canada, GeorgiaCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

Phase 2Anti-NMDAR Encephalitis

IA sessionRituximab

Assistance Publique - Hôpitaux de Paris20 participants1 site · FranceCompletes Jul 2024

Compare CT.gov Full analysis →

Recruiting

Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2Alzheimer DiseaseAgitation,PsychomotorCare Giving Burden

IGC-AD1-ActiveIGC-AD1-Placebo

IGC Pharma, LLC164 participants31 sites · United States, Canada, ColombiaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Phase 3Pediatric Migraine

Rimegepant/BHV3000Matching placebo

Pfizer2,100 participants246 sites · United States, Canada, ChinaCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGClopidogrel

Kafrelsheikh University900 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2Parkinson Disease

AP-472Placebo

Appello Pharmaceuticals, Inc.150 participants25 sites · United StatesCompletes Sep 2027

Compare CT.gov Full analysis →

1–15 of 160

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

160 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Phase 2Pediatric Epileptic SyndromePartial-onset Seizures

Perampanel Oral SuspensionPerampanel Tablet

Eisai Inc.100 participants49 sites · United States, Belgium, CzechiaCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Phase 1Phase 2Chronic Inflammatory Demyelinating PolyradiculoneuropathyNMO Spectrum DisorderMyasthenia Gravis

BAFF-R CART

Tianjin Medical University General Hospital27 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Phase 2Early Alzheimer's Disease

MK-2214Placebo

Merck Sharp & Dohme LLC340 participants78 sites · United States, Argentina, AustraliaCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants2 sites · United StatesCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Phase 3Alzheimers Disease

TrontinemabPlacebo

Hoffmann-La Roche800 participants143 sites · United States, Argentina, BrazilCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3Dravet Syndrome

zorevunersenSham Comparator

Stoke Therapeutics, Inc170 participants61 sites · United States, France, GermanyCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Phase 1Phase 2Amyotrophic Lateral Sclerosis (ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene

ALN-SODDiluentPlacebo (PB)

Regeneron Pharmaceuticals42 participants16 sites · Australia, Belgium, CanadaCompletes Jun 2031

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Phase 3Alzheimer's Disease

KarXTKarX-ECPlacebo

Bristol-Myers Squibb586 participants124 sites · United States, Argentina, AustraliaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3Dravet Syndrome

Clemizole HClPlacebo

Epygenix150 participants58 sites · United States, Canada, GeorgiaCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

Phase 2Anti-NMDAR Encephalitis

IA sessionRituximab

Assistance Publique - Hôpitaux de Paris20 participants1 site · FranceCompletes Jul 2024

Compare CT.gov Full analysis →

Recruiting

Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2Alzheimer DiseaseAgitation,PsychomotorCare Giving Burden

IGC-AD1-ActiveIGC-AD1-Placebo

IGC Pharma, LLC164 participants31 sites · United States, Canada, ColombiaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Phase 3Pediatric Migraine

Rimegepant/BHV3000Matching placebo

Pfizer2,100 participants246 sites · United States, Canada, ChinaCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGClopidogrel

Kafrelsheikh University900 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2Parkinson Disease

AP-472Placebo

Appello Pharmaceuticals, Inc.150 participants25 sites · United StatesCompletes Sep 2027

Compare CT.gov Full analysis →

1–15 of 160